NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis $2.34 +0.10 (+4.46%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Nautilus Biotechnology Stock (NASDAQ:NAUT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nautilus Biotechnology alerts:Sign Up Key Stats Today's Range$2.21▼$2.3550-Day Range$2.24▼$3.0852-Week Range$2.19▼$3.45Volume68,423 shsAverage Volume115,717 shsMarket Capitalization$293.81 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingModerate Buy Company OverviewNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Nautilus Biotechnology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks35th Percentile Overall ScoreNAUT MarketRank™: Nautilus Biotechnology scored higher than 35% of companies evaluated by MarketBeat, and ranked 768th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNautilus Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNautilus Biotechnology has received no research coverage in the past 90 days.Read more about Nautilus Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.57) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nautilus Biotechnology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.61% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.61% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous month News and Social MediaN/ANews SentimentN/A Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $234,729.00 in company stock.Percentage Held by Insiders40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nautilus Biotechnology's insider trading history. Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address NAUT Stock News HeadlinesNautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comNautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor ScrutinyOctober 31, 2024 | markets.businessinsider.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.November 21, 2024 | Darwin (Ad)Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator AwardOctober 31, 2024 | globenewswire.comNautilus Biotechnology Inc (NAUT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...October 30, 2024 | finance.yahoo.comNautilus Biotechnology Reports Q3 2024 Financial ResultsOctober 30, 2024 | msn.comNautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare ConferenceOctober 30, 2024 | globenewswire.comNautilus Biotechnology Reports Third Quarter 2024 Financial ResultsOctober 30, 2024 | markets.businessinsider.comSee More Headlines NAUT Stock Analysis - Frequently Asked Questions How have NAUT shares performed this year? Nautilus Biotechnology's stock was trading at $2.99 on January 1st, 2024. Since then, NAUT shares have decreased by 21.7% and is now trading at $2.34. View the best growth stocks for 2024 here. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Tuesday, October, 29th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04. Who are Nautilus Biotechnology's major shareholders? Top institutional shareholders of Nautilus Biotechnology include State Street Corp (0.74%), Wexford Capital LP (0.18%), Clearline Capital LP (0.11%) and Barclays PLC (0.08%). Insiders that own company stock include Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld, Perceptive Advisors Llc, Mary E Godwin and Matthew L Posard. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nautilus Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V). Company Calendar Last Earnings10/29/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:NAUT CUSIPN/A CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+92.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.85% Return on Assets-24.93% Debt Debt-to-Equity RatioN/A Current Ratio16.65 Quick Ratio16.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.10Miscellaneous Outstanding Shares125,564,000Free Float74,711,000Market Cap$293.82 million OptionableOptionable Beta1.23 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NAUT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.